Rentschler Biopharma SE, a CDMO for biopharmaceuticals, has completed the acquisition of a manufacturing facility from an affiliate of Shire plc. Rentschler Biopharma will continue to manufacture for Shire at the 93,000 sq.-ft. site in Milford, MA.

In addition, Rentschler Biopharma plans to further grow the development and manufacturing site to be leveraged as a CDMO for the development and manufacturing of complex biopharmaceuticals. The site has 70 employees that have been offered employment at the site. The site will be Rentschler Biopharma’s first facility outside of Germany and a key part of the company’s future growth plans. The purchase provides both expanded capacity and more flexibility to service client needs.

Dr. Frank Mathias, chief executive officer of Rentschler Biopharma, said, “The acquisition of this modern facility fits perfectly with our strategy to further strengthen and secure our world-class CDMO position in a growing and changing market. The U.S. is a key market for Rentschler Biopharma, and this site gives us a firm foothold in this important area of growth, enabling us to better meet our clients’ needs.”

Dr. Ralf Otto, chief operating officer of Rentschler Biopharma, added, “We will continue to make investments in our business to ensure we have the advanced technologies to remain an innovation leader in the field and the capacity to remain competitive and grow with our clients. This includes future plans to qualify the Milford site as a multi-product manufacturing facility.”
Financial terms of the transaction were not disclosed.